301 related articles for article (PubMed ID: 22666441)
1. Lack of correlation between outcomes of membrane repair assay and correction of dystrophic changes in experimental therapeutic strategy in dysferlinopathy.
Lostal W; Bartoli M; Roudaut C; Bourg N; Krahn M; Pryadkina M; Borel P; Suel L; Roche JA; Stockholm D; Bloch RJ; Levy N; Bashir R; Richard I
PLoS One; 2012; 7(5):e38036. PubMed ID: 22666441
[TBL] [Abstract][Full Text] [Related]
2. The phenotype of dysferlin-deficient mice is not rescued by adeno-associated virus-mediated transfer of anoctamin 5.
Monjaret F; Suel-Petat L; Bourg-Alibert N; Vihola A; Marchand S; Roudaut C; Gicquel E; Udd B; Richard I; Charton K
Hum Gene Ther Clin Dev; 2013 Jun; 24(2):65-76. PubMed ID: 23721401
[TBL] [Abstract][Full Text] [Related]
3. Defective membrane repair in dysferlin-deficient muscular dystrophy.
Bansal D; Miyake K; Vogel SS; Groh S; Chen CC; Williamson R; McNeil PL; Campbell KP
Nature; 2003 May; 423(6936):168-72. PubMed ID: 12736685
[TBL] [Abstract][Full Text] [Related]
4. A naturally occurring human minidysferlin protein repairs sarcolemmal lesions in a mouse model of dysferlinopathy.
Krahn M; Wein N; Bartoli M; Lostal W; Courrier S; Bourg-Alibert N; Nguyen K; Vial C; Streichenberger N; Labelle V; DePetris D; Pécheux C; Leturcq F; Cau P; Richard I; Lévy N
Sci Transl Med; 2010 Sep; 2(50):50ra69. PubMed ID: 20861509
[TBL] [Abstract][Full Text] [Related]
5. Efficient recovery of dysferlin deficiency by dual adeno-associated vector-mediated gene transfer.
Lostal W; Bartoli M; Bourg N; Roudaut C; Bentaïb A; Miyake K; Guerchet N; Fougerousse F; McNeil P; Richard I
Hum Mol Genet; 2010 May; 19(10):1897-907. PubMed ID: 20154340
[TBL] [Abstract][Full Text] [Related]
6. Dysferlin function in skeletal muscle: Possible pathological mechanisms and therapeutical targets in dysferlinopathies.
Cárdenas AM; González-Jamett AM; Cea LA; Bevilacqua JA; Caviedes P
Exp Neurol; 2016 Sep; 283(Pt A):246-54. PubMed ID: 27349407
[TBL] [Abstract][Full Text] [Related]
7. Expression of myoferlin in skeletal muscles of patients with dysferlinopathy.
Inoue M; Wakayama Y; Kojima H; Shibuya S; Jimi T; Oniki H; Nishino I; Nonaka I
Tohoku J Exp Med; 2006 Jun; 209(2):109-16. PubMed ID: 16707852
[TBL] [Abstract][Full Text] [Related]
8. Disruption of muscle membrane and phenotype divergence in two novel mouse models of dysferlin deficiency.
Ho M; Post CM; Donahue LR; Lidov HG; Bronson RT; Goolsby H; Watkins SC; Cox GA; Brown RH
Hum Mol Genet; 2004 Sep; 13(18):1999-2010. PubMed ID: 15254015
[TBL] [Abstract][Full Text] [Related]
9. Dysferlin stabilizes stress-induced Ca2+ signaling in the transverse tubule membrane.
Kerr JP; Ziman AP; Mueller AL; Muriel JM; Kleinhans-Welte E; Gumerson JD; Vogel SS; Ward CW; Roche JA; Bloch RJ
Proc Natl Acad Sci U S A; 2013 Dec; 110(51):20831-6. PubMed ID: 24302765
[TBL] [Abstract][Full Text] [Related]
10. Membrane damage-induced vesicle-vesicle fusion of dysferlin-containing vesicles in muscle cells requires microtubules and kinesin.
McDade JR; Michele DE
Hum Mol Genet; 2014 Apr; 23(7):1677-86. PubMed ID: 24203699
[TBL] [Abstract][Full Text] [Related]
11. Treatment with Recombinant Human MG53 Protein Increases Membrane Integrity in a Mouse Model of Limb Girdle Muscular Dystrophy 2B.
Gushchina LV; Bhattacharya S; McElhanon KE; Choi JH; Manring H; Beck EX; Alloush J; Weisleder N
Mol Ther; 2017 Oct; 25(10):2360-2371. PubMed ID: 28750735
[TBL] [Abstract][Full Text] [Related]
12. Myoferlin, a candidate gene and potential modifier of muscular dystrophy.
Davis DB; Delmonte AJ; Ly CT; McNally EM
Hum Mol Genet; 2000 Jan; 9(2):217-26. PubMed ID: 10607832
[TBL] [Abstract][Full Text] [Related]
13. New aspects on patients affected by dysferlin deficient muscular dystrophy.
Klinge L; Aboumousa A; Eagle M; Hudson J; Sarkozy A; Vita G; Charlton R; Roberts M; Straub V; Barresi R; Lochmüller H; Bushby K
J Neurol Neurosurg Psychiatry; 2010 Sep; 81(9):946-53. PubMed ID: 19528035
[TBL] [Abstract][Full Text] [Related]
14. Dysferlin associates with the developing T-tubule system in rodent and human skeletal muscle.
Klinge L; Harris J; Sewry C; Charlton R; Anderson L; Laval S; Chiu YH; Hornsey M; Straub V; Barresi R; Lochmüller H; Bushby K
Muscle Nerve; 2010 Feb; 41(2):166-73. PubMed ID: 20082313
[TBL] [Abstract][Full Text] [Related]
15. Translational research and therapeutic perspectives in dysferlinopathies.
Barthélémy F; Wein N; Krahn M; Lévy N; Bartoli M
Mol Med; 2011; 17(9-10):875-82. PubMed ID: 21556485
[TBL] [Abstract][Full Text] [Related]
16. Systemic Delivery of Dysferlin Overlap Vectors Provides Long-Term Gene Expression and Functional Improvement for Dysferlinopathy.
Potter RA; Griffin DA; Sondergaard PC; Johnson RW; Pozsgai ER; Heller KN; Peterson EL; Lehtimäki KK; Windish HP; Mittal PJ; Albrecht DE; Mendell JR; Rodino-Klapac LR
Hum Gene Ther; 2018 Jul; 29(7):749-762. PubMed ID: 28707952
[TBL] [Abstract][Full Text] [Related]
17. DYSF mutation analysis in a group of Chinese patients with dysferlinopathy.
Zhao Z; Hu J; Sakiyama Y; Okamoto Y; Higuchi I; Li N; Shen H; Takashima H
Clin Neurol Neurosurg; 2013 Aug; 115(8):1234-7. PubMed ID: 23254335
[TBL] [Abstract][Full Text] [Related]
18. [Amyloidosis in muscular dystrophy].
Carl M; Röcken C; Spuler S
Pathologe; 2009 May; 30(3):235-9. PubMed ID: 19326120
[TBL] [Abstract][Full Text] [Related]
19. Lipid accumulation in dysferlin-deficient muscles.
Grounds MD; Terrill JR; Radley-Crabb HG; Robertson T; Papadimitriou J; Spuler S; Shavlakadze T
Am J Pathol; 2014 Jun; 184(6):1668-76. PubMed ID: 24685690
[TBL] [Abstract][Full Text] [Related]
20. Dysferlin and the plasma membrane repair in muscular dystrophy.
Bansal D; Campbell KP
Trends Cell Biol; 2004 Apr; 14(4):206-13. PubMed ID: 15066638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
